Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,904 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06518655Recruiting
Can a breath test tell if a lung nodule is cancer?
This trial is testing a simple breath test to see if it can tell whether a lung nodule is cancer or not. If you have a lung nodule that will be removed by surgery, you may be able to help find out if breathing into a device can replace more invasive tests.
Beijing, Beijing MunicipalityAges 18–80 - NCT06524427Recruiting
Robot vs. video-assisted lung cancer surgery study
This trial compares robot-assisted surgery to video-assisted surgery for removing lung cancer. It aims to see which approach works better for patients with early-stage non-small cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06536868RecruitingPhase 2
Tislelizumab with chemo and radiation for extensive-stage small cell lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Jincheng, ShanxiAges 18–80 - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT06573073Recruiting
Lung cancer test for EGFR T790M mutation
This trial tests a new blood test that can detect a specific genetic change (EGFR T790M) in advanced lung cancer. It aims to see if the test works well for guiding treatment decisions.
TaipeiAges 18 years+ - NCT06574295Recruiting
Lung surgery without a breathing tube
This study compares two types of lung surgery for people with lung nodules or lung cancer: one with a breathing tube (standard) and one without (non-intubated). The goal is to see if the non-intubated approach is safer and helps you recover faster.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06607796RecruitingPhase 3
PTS injection for stage 4 lung cancer without gene mutations
This trial tests injecting a drug called PTS directly into lung tumors for people with stage 4 non-small cell lung cancer that doesn't have certain gene changes. It is for patients whose tumors have stayed stable after first-line treatment and are located in a small area of the outer lung.
Guangzhou, GuangdongAges 18–75 - NCT06616766RecruitingPhase 1/Phase 2
Study of a new drug for advanced cancers with HER2 or EGFR changes
This trial tests a new medication (YH42946) for people with advanced solid tumors that have specific genetic changes in HER2 or EGFR. It aims to see if the drug is safe and effective for those who have exhausted other treatments.
Fairfax, VirginiaAges 18 years+ - NCT06617416RecruitingPhase 3
AK104 for locally advanced lung cancer after chemoradiotherapy
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
JinanAges 18 years+ - NCT06618599Recruiting
Two numbing injections for pain after lung cancer surgery
This study compares two types of numbing injections (one around the spine and another near the back muscles) to see which works better for pain relief after lung cancer surgery. It may help you have less pain and need fewer pain medicines.
CairoAges 18–65 - NCT06644066Recruiting
Oxygen-guided lung surgery for small tumors
This trial tests a new way to help surgeons find the right boundary between lung segments during surgery, using oxygen levels to guide them. It may help patients with small, early-stage lung tumors.
Xi'an, ShaanxiAges 18–75 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06702826RecruitingPhase 2
Cadonilimab plus radiation for lung cancer brain mets
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
Changsha, HunanAges 18–75 - NCT06707519Recruiting
Lung cancer breath and blood test study
This study is testing new breath and blood tests to detect lung cancer. It may help find better ways to diagnose and monitor non-small cell lung cancer.
Hamilton, OntarioAges 18 years+ - NCT07518160RecruitingPhase 2
JS212 and JS111 for advanced lung cancer with EGFR mutations
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT06732193Recruiting
Fissios App for recovery after lung cancer surgery
This trial tests whether using a smartphone app (Fissios) after lung cancer surgery helps you recover with fewer complications. If you are scheduled for lung surgery for non-small cell lung cancer and have a smartphone, you may be eligible.
Madrid, MadridAges 18 years+ - NCT06749691RecruitingPhase 2
Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06754930RecruitingPhase 1/Phase 2
Study of SHR-1826 combined with other treatments for lung cancer
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06756217Recruiting
PET scan to check early response to immunotherapy before lung cancer surgery
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06780826Recruiting
Atezolizumab plus chemo for extensive-stage small cell lung cancer
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
ShanghaiAges 18 years+ - NCT06800586Recruiting
Air pollution and health: new early warning signs
This study looks for new early warning signs (biomarkers) of how air pollution affects lung and blood health. It is for people with COPD, lung cancer, or leukemia who have never smoked much, as well as for healthy hospital workers.
Bologna, BolognaAges 18 years+ - NCT06810375RecruitingPhase 3
Nerve Blocks for Pain After Video-Assisted Lung Surgery
This trial tests two different numbing shots (nerve blocks) to see which one works better for pain after video-assisted lung surgery. One block is placed near the spine, and the other is between the ribs. The goal is to find the best way to keep you comfortable after surgery.
Washington D.C., District of ColumbiaAges 18–90
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,904 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.